Monitor commercial launch execution and prescription uptake in H2 2026. The approval is a positive pipeline catalyst but not transformative for GSK's top line. Spero Therapeutics (SPRO) may see a more pronounced move given its smaller market cap and reliance on this asset.
GSK drugs
GSK drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 17 $52.15entry
- T+1 · 5mo ago −2.84%α −3.62% · $50.67
- T+5 · 5mo ago −2.03%α −0.99% · $51.09
- T+20 · 4mo ago +1.19%α −0.13% · $52.77
- T+60 · 2mo ago −7.71%α −10.86% · $48.13
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announces FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic for complicated urinary tract infections (cUTIs) in adults. The approval is based on the PIVOT-PO phase III trial demonstrating non-inferiority to intravenous imipenem-cilastatin. This expands GSK's anti-infectives portfolio and addresses a significant unmet need, though near-term financial impact is modest relative to GSK's $106.5B market cap.
Key Facts
- FDA approved Utebzi (tebipenem pivoxil) for cUTIs including pyelonephritis in adults with limited/no oral alternatives.
- First and only oral carbapenem antibiotic approved in the US.
- PIVOT-PO trial showed 58.5% overall success rate for tebipenem pivoxil vs 60.2% for IV imipenem-cilastatin (adjusted difference -1.3%; 95% CI -7.5%, 4.8%).
- Product anticipated to be available to US patients by end of 2026.
- Approval builds on GSK's exclusive global licensing agreement with Spero Therapeutics (Nasdaq: SPRO) from September 2022.
Financial Impact
No specific revenue guidance provided; addresses a US market with >3 million annual cUTI cases and >$6 billion in annual healthcare costs. Modest near-term contribution to GSK's overall revenue.
Risk Factors
- Pricing and reimbursement challenges in the US antibiotic market.
- Competition from existing IV carbapenems and other oral antibiotics for cUTI.
- Adoption may be limited to patients with no alternative oral options per label.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-006036 |
| Document: 0001654954-26-006036-index-headers.html | 0001654954-26-006036 |
| Document: 0001654954-26-006036-index.html | 0001654954-26-006036 |
| Document: 0001654954-26-006036.txt | 0001654954-26-006036 |
Track record
64 reports on GSK
8 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers